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Aim: To investigate the value of measuring liver enzymes, red cell distribution width (RDW), and mean platelet volume (MPV) in
predicting the development of gestational diabetes mellitus (GDM).
Materials and methods: The medical records of all pregnant women followed by the obstetrics clinic between January 2010 and
November 2012 were systematically evaluated, and patients with a diagnosis of GDM were identified. A total of 68 patients with GDM
and 61 healthy controls were included in the study. Results of relevant laboratory parameters were recorded.
Results: Out of all the parameters evaluated, mean values for platelet distribution width (PDW) and mean activities of alanine
transaminase (ALT) and γ-glutamyl transferase (GGT) were significantly higher in the GDM group compared to healthy controls (P =
0.003, P = 0.015, and P = 0.021, respectively), whereas mean plateletcrit (PCT) levels were significantly lower in the GDM group (P =
0.002). No significant difference was observed between groups in terms of MPV, RDW, platelet count, and aspartate transaminase levels.
Conclusion: Our study results suggest that ALT, GGT, PCT, and PDW may be useful as predictors of impending GDM.
Key words: Gestational diabetes, alanine transaminase, γ-glutamyl transferase, platelet count, platelet distribution width

1. Introduction
Gestational diabetes mellitus (GDM) is a condition
in which, during pregnancy, glucose intolerance and
complex metabolic and hormonal changes occur. On the
other hand, diabetic women who become pregnant are not
classified with this condition. Prevalence of GDM ranges
from <1% to 20% according to the data from developed
countries. Due to the increased risk of developing future
glucose intolerance and perinatal morbidity and mortality
risk, diagnosis of GDM is very important (1,2).
Previous studies have investigated the activity of
γ-glutamyl transferase (GGT), aspartate transaminase
(AST), and alanine transaminase (ALT) as markers for
impending impairment of glucose metabolism with
conflicting results (3,4).
Red cell distribution width (RDW), which is calculated
by most modern hemoanalyzers, quantifies variability in
the size of circulating red blood cells with lower values
indicating greater homogeneity in cell sizes. Although
the most common clinical use of RDW, developed via red
cell size distribution histograms, has been to distinguish
* Correspondence: sevilaysezer@gmail.com

between etiologies of microcytic anemia and macrocytic
anemia (5), several recent studies portrayed high RDW as
an indicator of poor cardiovascular fitness as well as being
associated with higher mortality rates in chronic heart
failure (6). It has also been linked with an increased risk of
death in patients with pulmonary hypertension (7).
Nearly 30 years ago Thompson et al. (8) postulated
on the effect of platelet size on platelet aggregation.
Mean platelet volume (MPV), which indicates platelet
size, has subsequently been shown to increase in patients
with coronary artery disease, diabetes mellitus (DM),
thrombotic events, and other inflammatory disorders
(9–11). The relationship between high MPV and GDM
has been previously established in several studies (12,13).
The prognostic values of RDW, AST, ALT, and GGT have
been demonstrated in numerous studies on patients with
DM (3,14,15). To the best of our knowledge, a similar
evaluation of these 5 parameters in patients with GDM has
not been published to date, and the aim of this study was to
investigate the potential role of several hematological and
biochemical parameters in predicting GDM.
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2. Materials and methods
This retrospective study was undertaken at the Ankara
Numune Training and Research Hospital with the approval
of the local ethics committee.
In our hospital, all pregnant women are screened for
GDM by a 1-h 50-g oral glucose tolerance test (OGTT)
performed between 24–28 weeks of gestation. In patients
with a blood glucose level of more than 140 mg/dL, the
diagnosis of GDM is confirmed by a subsequent 3-h 100-g
OGTT according to international guidelines (1).
Patients with anemia, a previous diagnosis of DM,
preeclampsia, active smoking habit, history of alcohol
consumption, chronic viral hepatitis (hepatitis B surface
antigen or anti-HCV positivity), HIV infection, or any
other chronic disorders were excluded from the study.
Patients were also required to have values for prothrombin
time (PT), international normalized ratio (INR), white
blood cell (WBC) count, and renal function tests within
normal ranges to be eligible for inclusion in the study. The
control group consisted of pregnant women who did not
meet the criteria for GDM during the same study period.
Following screening for eligibility, the records of 68
patients with GDM and 61 healthy controls were deemed
suitable for inclusion in the final analysis.
Relevant demographic information such as maternal
and gestational age was retrieved from the medical
records. Hematological parameters, which were measured
by an automated hemoanalyzer (Sysmex XE-2100; Sysmex,
Kobe, Japan), were also recorded, including hemoglobin
(Hb), hematocrit (Hct), red blood cell (RBC) count,
RDW, platelet (PLT) count, MPV, platelet distribution
width (PDW), plateletcrit (PCT), and WBC count. Serum
activity of AST, ALT, GGT, creatinine, and urea, as well

as results of all blood glucose measurements, which were
taken using a commercial biochemistry analyzer (Roche
P800 MODULAR; Roche Diagnostics, Indianapolis, IN,
USA), were noted. Coagulation parameters were evaluated
using a blood coagulation device (STA-Compact Analyzer;
Diagnostica Stago-Roche, Mannheim, Germany), and
values for activated partial thromboplastin time (aPTT),
PT, and INR were recorded for each patient.
Statistical analyses were performed using PASW
Statistics 18 software. Normality of distribution for
continuous variables was evaluated using the Kolmogorov–
Smirnov test, and comparisons between groups for
variables with a normal distribution were made using the
Student t-test with values provided as mean ± standard
deviation (SD). The Mann–Whitney U test was used for
comparisons of parameters with an abnormal distribution,
the values of which are given as medians (minimum–
maximum). A P-value of less than 0.05 was considered
indicative of statistical significance.
3. Results
Ages of the patients with GDM and healthy controls
included in the study were 31.84 ± 5.67 and 25.57 ± 5.30
years, respectively. Out of all the parameters evaluated,
mean value for PDW and mean activity of ALT and GGT
were significantly higher in the GDM group compared
to healthy controls (P = 0.003, P = 0.015, and P = 0.021,
respectively), whereas mean PCT levels were significantly
lower in the GDM group (P = 0.002). There was no
difference between the groups in terms of mean RDW,
MPV, PLT, and AST. Results have been summarized in the
Table.

Table. Characteristics of patients and controls.
Parameters

Control (n = 61)

GDM (n = 68)

P

ALT (IU/L) [median (min–max)]

10.50 (4–29)

12 (3–42)

0.015

GGT (IU/L) [median (min–max)]

8 (3–59)

9 (3–37)

0.021

AST (IU/L) [median (min–max)]

16 (11–53)

17.50 (11–30)

ns

RDW [median (min–max)]

14.3 (13.00–22.90)

14.4 (12.3–17.00)

ns

PLT (×10 /L) (mean ± SD)

239.26 ± 90.37

214.62 ± 67.91

ns

MPV (mean ± SD)

11.15 ± 1.14

10.50 ± 2.94

ns

PDW (mean ± SD)

14.56 ± 2.80

16.19 ± 2.42

0.003

PCT [median (min–max)]

0.25 (0.10–0.55)

0.20 (0.11–0.59)

0.002

9

GDM: gestational diabetes mellitus, SD: standard deviation, ns: not significant, ALT: alanine aminotransferase, GGT:
γ-glutamyl transferase, AST: aspartate aminotransferase, RDW: red blood cell distribution width, PLT: platelet count,
MPV: mean platelet volume, PDW: platelet distribution width, PCT: plateletcrit.
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4. Discussion
GDM is estimated to develop in up to 28% of pregnancies
(2) with serious implications on fetal health, such as
increased risks of macrosomia, bone fractures, nerve
damage, and other biochemical disorders. Mothers with
GDM are more than 50% more likely to develop overt
DM within 10 years of initial diagnosis (16). The shortand long-term fetal/maternal risks associated with GDM
highlight the importance of timely recognition and
management of the condition.
Our study results suggest that among the parameters
evaluated, GGT, ALT, PDW, and PCT could be useful as
predictors of pregnancies with the potential of developing
GDM. In recent years, several studies have investigated the
predictive value of liver enzymes, and elevated GGT levels
in particular have been found to be significantly correlated
with impaired glucose tolerance (3,4). Other studies have
demonstrated an increased risk of developing DM in the
future in pregnant women with elevated ALT and GGT
activities, and that liver steatosis and hepatic insulin
resistance play a role in this process (4,17). Additionally,
GGT has been shown to facilitate the stress response of the
endoplasmic reticulum (15). In our study, the GDM group
had significantly higher mean GGT and ALT activities
than the healthy controls. While our findings conflict
with those of previous studies on patients with GDM (8),
similar results have been reported in patients with DM (4).
RDW is a measure of variability in the size of
circulating erythrocytes (5) that is routinely calculated
by automated hemoanalyzers. In a previous study, it was
suggested that increased RDW may be associated with an
increased risk of all-cause mortality in patients with DM
(14). In a subsequent metaanalysis including 7 studies
published in 2010, Patel et al. (14) managed to confirm the
presence of an added risk posed by elevated RDW. It was
reported that a 1% increment in RDW increased mortality
risk by 14% regardless of hemoglobin concentration in all
7 studies of the metaanalysis. In the third National Health
and Nutrition Examination Survey study, higher RDW
values were found to be associated with an increased risk
of developing nephropathy in patients with DM (18). In
another prospective study, patients with diabetic foot
osteomyelitis had higher RDW values by the end of 1 year
compared to a control group (19). In a different study by
Johnston et al. (20), no significant association between
RDW values and risk of celiac disease was observed in
patients with insulin-dependent DM. We also could not
demonstrate the presence of a significant link between
RDW and risk of developing GDM.
The mechanism(s) responsible for the increase in
RDW values in patients with DM remain elusive. RDW
has previously been shown to be an indirect indicator
of nutritional status, anemia, inflammation, and several

age-associated diseases (14), and higher values have
been linked with increased morbidity and mortality.
Although erythrocytes are equipped with extensive
antioxidant systems, reactive oxygen species, which are
produced on membrane surfaces and eventually released
into circulation, contribute towards their elimination by
the reticuloendothelial system, thus resulting in higher
RDW values (21). Inflammatory cytokines as well as an
increase in circulating erythropoietin production have
been implicated as contributors to the increase in RDW
(22). However, RDW has also been shown to be affected
by nutritional deficiencies and other conditions leading
to inadequate production of erythropoietin (6). All the
participants in our study were taking multivitamin/
iron supplements, which may explain the statistical
insignificance of the RDW values observed.
Numerous studies have firmly established a link
between MPV, which indicates platelet size, and DM
(9,10,23,24). According to the National Health and
Nutrition Examination Survey study, participants with
DM and poor glycemic control had significantly higher
MPV values than healthy controls (24). In another study,
Kodiatte et al. (9) demonstrated significantly higher MPV
values in patients with DM compared to a nondiabetic
control group. They also observed that patients with
DM had higher PLT counts, although the difference was
statistically insignificant. PDW, investigated in a similar
setting, was also found to be significantly higher in
diabetic individuals compared to healthy controls (23).
In the same study, mean PDW, but not MPV, was found
to be significantly different in diabetic patients with
complications compared to those with noncomplicated
DM (23). Kodiatte et al. observed higher mean MPV in
diabetic subjects with microvascular complications than
in those without complications, although the difference
was statistically insignificant (9).
MPV was reported to be an independent predictor of
morbidity in women with GDM in 2 different studies by
Bozkurt et al. (13) and Erikçi et al. (12). Our study differs
from those studies in that we investigated the value of
measuring MPV during early pregnancy as a predictor
of impending GDM. We did not observe a significant
difference between groups in terms of PLT count, a
finding shared by Bozkurt et al. (13). Furthermore, as
reported in the study by Erikçi et al. (12), we demonstrated
significantly higher PDW values in patients with GDM
compared to healthy controls. Our study also differs from
that by Erikçi et al. (12) in that we observed significantly
lower PCT values in patients with GDM.
It has been suggested that platelets and the coagulation
system are important determinants of atherogenesis and
atherothrombosis (25). Although diabetes is considered
a “prothrombotic state”, the underlying mechanism
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behind increased platelet reactivity and higher MPV in
diabetic subjects is not completely understood (9). DMassociated thrombocytopathy could be due to reduced
membrane fluidity; altered Ca2+ and Mg2+ homeostasis;
increased arachidonic acid metabolism and thromboxane
A2 (TXA2) synthesis; decreased prostacyclin production,
nitric oxide production, and antioxidant levels; and
increased expression of activation-dependent adhesion
molecules (26). Increased MPV, on the other hand, may be
explained by the osmotic swelling effect of hyperglycemia
as well as the effects of insulin, which increases platelet
turnover, resulting in an increase in the number of younger
and consequently larger platelets (9). Tschope et al. (25)
also suggested that glycoprotein IB expression, which
plays an important role in thrombus formation, increases
in patients with diabetes.
It has been well documented that larger platelets are
younger with more potent metabolic and enzymatic
activity, making them more “agreeable” (9). However,
accurate measurement of platelet indices requires
diligence since results may be affected by several factors,
such as anticoagulants used after blood sampling, storage
temperature, and processing delays (11). For example,
platelets have been shown to swell with time when they are
stored in tubes containing ethylenediaminetetraacetic acid

(EDTA) as an anticoagulant, resulting in a time-dependent
increase in MPV (11).
The main limitation of this study is its retrospective
nature, which translates to many factors being beyond our
control. It has been established that blood samples need to
be processed within 1 h if stored in tubes containing EDTA
to prevent platelet swelling (11), and unfortunately the
medical records of our study population did not contain
any information regarding the processing time. Even
though our hospital has a “rapid transfer and processing”
policy for blood samples during the preanalytic stage,
the time factor would have been better controlled in a
prospective study. Another limitation of this study is the
small number of patients, as well as the age difference
between patients with and without GDM, which may have
affected the study results.
Our results show that ALT, GGT, and some platelet
indices may be useful in predicting the development of
GDM, a condition with potentially serious complications.
Very few studies have investigated the possible link between
MPV and GDM, and to the best of our knowledge, this is
the first study to evaluate RDW as a predictor of GDM.
There is a need for more comprehensive prospective
studies on larger study populations to help better identify
predictors of GDM.
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